Tesamorelin (Egrifta): what it's actually FDA-approved for, and the evidence

Tesamorelin occupies an unusual spot in the peptide world: it is one of the few growth-hormone-related peptides that is an actual FDA-approved drug, sold as Egrifta. That makes it a useful reference point for separating what a GHRH analog is genuinely approved to do from what the longevity market wishes it did. The two are not the same thing, and the gap between them is the whole point of this piece.

What it is and how it works

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH). Rather than supplying growth hormone directly, it stimulates the pituitary to secrete the body's own GH in a more physiologic, pulsatile pattern, which in turn raises IGF-1.^[1] This indirect mechanism is a deliberate design choice: it preserves feedback regulation in a way that exogenous GH injections do not. The downstream metabolic effect of interest is a reduction in visceral adipose tissue — the deep abdominal fat associated with cardiometabolic risk.

The approved indication — and only that

The FDA approval is narrow and specific: tesamorelin is indicated to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, a condition in which antiretroviral therapy can drive abnormal visceral-fat accumulation.^[2] The pivotal evidence came from randomized, placebo-controlled Phase 3 trials in this population, which showed that tesamorelin significantly reduced visceral adipose tissue versus placebo, with reductions that reversed after stopping the drug.^[3] Note the precision required here: the approval is for visceral-fat reduction in HIV-associated lipodystrophy — it is not an approval for general weight loss, bodybuilding, anti-aging, or healthspan extension.

The off-label and longevity uses

Because tesamorelin raises GH and IGF-1 and trims visceral fat, it has been adopted off-label and in the “research peptide” market for anti-aging, body composition and metabolic goals in people without HIV. Some legitimate investigational work exists adjacent to this — for instance, exploration of GHRH analogs in the context of fatty-liver biology and cognition in aging — but the evidence base for tesamorelin specifically as a longevity or healthspan intervention in healthy adults is not established.^[4] Using an HIV-lipodystrophy drug for healthy-adult anti-aging is an extrapolation from a different population to a different goal.

The caveats that come with raising GH

Stimulating the GH/IGF-1 axis is not consequence-free. Tesamorelin can raise blood glucose and worsen glucose tolerance, and IGF-1 elevation is the reason GH-axis interventions carry theoretical concern around tissue growth — which is precisely why approved use involves monitoring. The approved product also carries specific contraindications and warnings. None of these safeguards apply to peptides bought from an unregulated “research-use-only” supplier, where dose, purity and identity are unverified on top of the off-label-population question.

The honest bottom line

Tesamorelin is real, approved, and supported by genuine Phase 3 data — for one thing: reducing visceral fat in adults with HIV-associated lipodystrophy. That FDA approval should not be silently upgraded into an endorsement of tesamorelin as an anti-aging or general fat-loss therapy, where the evidence in healthy adults simply isn't there. Approved-for-X does not mean proven-for-Y, and with a drug that deliberately raises the GH/IGF-1 axis, the distinction is not academic.